You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 236 No. 25, December 20, 1976 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Evaluation of a new aerosolized steroid for asthma therapy: beclomethasone dipropionate (Vanceril inhaler)

J. C. Ballin

Beclomethasone dipropionate, an esterified derivative of betamethasone, can be given in small doses in aerosol form to patients with severe asthma whose symptoms cannot be controlled with nonsteroidal agents (bronchodilators and cromolyn). Many asthmatic patients who previously required systemic steroids can be transferred to this safer anti-inflammatory agent. In usual doses, beclomethasone produces few, if any, systemic side effects. The only susbstantial reaction is Candida infections of the oropharynx and larynx.





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1976 American Medical Association. All Rights Reserved.